About
Gyre Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
Mar 17 2026
Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
Mar 12 2026
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Mar 2 2026
Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline
Jan 5 2026
Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting
Nov 7 2025
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
Recent Videos

GNIが急成長する本当の理由|中国で稼ぎ、米国で評価されるバイオ株
Dec 21, 2025

POTENTIAL UPSIDE : GYRE STOCK ANALYSIS | GYRE THERAPEUTICS INC STOCK
Nov 19, 2025

My key insight from Gyre Therapeutics' latest financial report
Nov 11, 2025

My Key Financial Takeaway from Gyre Therapeutics' Report
Aug 13, 2025
Translate